

## INDEX

### A

- Accreditation Council for Graduate Medical Education (ACGME) Outcome Project, 134–138  
assessment of performance, 136–138
- Adolescent primary care, school-based health centers as model for provision of, **113–121**
- Adrenal insufficiency, recombinant human growth hormone therapy and, 229
- Adrenarche, premature, 248–250
- Adrenocorticotropin, 269
- Anemia, prevention of, 29–33
- Angiogenesis inhibitors, in neuroblastoma, 307
- Antiepileptic drugs, 264–267  
choice of, based on potential toxicity, 267  
based on seizure type and syndrome, 266  
narrow-spectrum, 266  
newest, 268–269
- Antipsychotics, 168–173  
in autism, 172  
mechanism of action of, 169  
monitoring during use of, 173  
side effects of, 169–171  
summary of, 172  
traditional versus newer, 171–172
- Anxiety disorders, in children, 155–156
- Atomoxetine, 167–168
- Atopic disease, nutritional interventions for prevention of, 27–29
- Atropine, in infantile hypertrophic pyloric stenosis, 198–199
- Attention-deficit/hyperactivity disorder, 156–158, 166
- Auditory neuropathy spectrum disorder, 277, 283
- Aurora A kinase, in neuroblastoma, 306
- Autism, 158  
antipsychotics in, 172

selective serotonin reuptake inhibitors in, 163–164

### B

- Behavioral disorders, medication in management of, 155
- Breast, development of, body mass index and, 247–248  
leptin and, 247
- Breastfeeding, and atopic disease, 28

### C

- Capital femoral epiphysis, slipped, recombinant human growth hormone therapy and, 229–230
- Cardiovascular health, lipid screening and, 35–36
- Catheter-related infections, after transplantation, recombinant human growth hormone therapy and, 230  
pediatric intestinal failure and, 189
- Central nervous system infections, caused by human *Parechoviruses*, 70–73
- Child health, global, leadership in, definition of, 15  
developing of, **11–16**  
for improvements in, 11–12  
in developing countries, 16–24  
meaning of, 16  
leadership in developing countries, communication in, 20–21  
health system planning and, 23–24  
management of conflict and change in, 22  
personalities and motivations and, 19–20  
politics of health and, 22  
scope of problem, 19  
team building for, 21–22  
vision and, 20  
leadership programs in, 17, 18

Note: Page numbers of article titles are in **boldface** type.

- Cochlear implantation, hearing loss and, in children, **277–296**
- Cochlear implant(s), **278–280**  
 activation following surgery, **289–290**  
 bacterial meningitis and, **285**  
 bilateral implantation of, **290–291**  
 candidacy for, **281–284**  
 cost effectiveness of, and quality of life, **292–293**  
 goal of, **291**  
 outcomes of, **291–292**  
 procedure for, **286–289**  
 surgical and medical considerations for, **285–286**

---

**D**

- Deaths, childhood, reduction of, failure of, **14**
- Depression, in children, **156**
- Diabetes mellitus, recombinant human growth hormone therapy and, **228**

---

**E**

- Education, pediatric. See *Pediatric education*.
- Electroclinical syndromes, and epilepsies, **262**
- Encephalitis, caused by human *Parechoviruses*, **73**
- Epilepsy, classification of, **261**  
 electroclinical syndromes and, **262**  
 pediatric, management of, example case in, **270–271**  
 nonmedication treatment of, **272–274**  
 surgery in, **274**  
 update on, **259–276**  
 seizures and, approach to, **261–264**  
 classification of, **259–261**

---

**F**

- Febrile illness, undifferentiated, caused by human *Parechoviruses*, **73–74**
- Flaccid paralysis, acute, caused by human *Parechoviruses*, **72–73**
- Foster care, recent developments in, **87–88**
- Foster child, abuse and neglect of, **95**  
 care of, primer for the pediatrician, **87–111**  
 communication skills and, **92–96**  
 cultural issues and, **106**  
 educational advocacy for, **97–100**  
 environmental risk factors for, **88–89**  
 foster parent and, **105–106**  
 language delays in, screening for, **93–94**  
 language disorders in, **93**  
 language stimulation of, **94–95**  
 medical focus on, **88–92**

- mental health care for, **100–103**  
 postplacement comprehensive medical care for, **89–92**  
 prenatal exposure to alcohol and drugs, language development and, **96**  
 psychosocial issues and, **103–105**  
 speech disorders in, **93**

Foster parent, and foster child, **105–106**

---

**G**

- Gastrin-releasing peptide receptors, in neuroblastoma, **309**
- Gastrointestinal disease, caused by human *Parechoviruses*, **75–76**
- Generations at Work*, medical education and, **133–134**
- Glutamine, in pediatric intestinal failure, **190**
- Growth hormone, recombinant human, efficacy of, **209–219**  
 future directions in, **233**  
 indications for, **207, 208**  
 mortality risk associated with, **221–222**  
 risk of malignancy associated with, **223–227**  
 safety of, **219–233**  
 and efficacy update on, **207–241**
- Growth hormone deficiency, pediatric, recombinant human growth hormone therapy and, **209–211, 212**

---

**H**

- Haemophilus influenzae* type B-*Neisseria meningitidis* serogroups C and Y-tetanus toxoid conjugate vaccine, **56–57**
- Hair, genital, appearing in infancy, **251**
- Health, child. See *Child health*.
- Hearing loss, and cochlear implantation in children, **277–296**  
 sensorineural, **278**  
 types of, **277**
- Hemorrhage-hepatitis syndrome, human *Parechoviruses* in, **74**
- Human papilloma virus vaccines, **53–54**
- Hypertension, intracranial, recombinant human growth hormone therapy and, **228**

---

**I**

- Illnesses, childhood, integrated management of, **12–13**
- Immunization(s), adolescent, **50–51**  
 update III, **41–64**

- Immunotherapy, in neuroblastoma, 306–307
- Influenza, seasonal, 49–54
- Influenza A, 2009 (H1N1) novel, 41–49
- Influenza vaccines, 41–54
  - AAP recommendations for 2010–2011 season, 49
  - currently available (2010–2011), 50
- Intestinal failure, pediatric, assessment in, 183
  - bacterial overgrowth and, 187
  - catheter-related infections and, 189
  - complications associated with, 187–189
  - feeding strategies in, 183–185
  - management of, **181–194**
    - at birth, 182–183
    - new concepts in, 189–191
    - prognosis in, factors associated with, 185–187
- Iron deficiency, prevention of, 29–33
- Iron intake, for infants, 31

**L**

- Lacosamide, 268–269
- Leadership Training Program in Global Child Health, 24–25
- Leptin, development of breast and, 247
- Lipid screening, and cardiovascular health, 35–36
- Low-fat dairy products, in obesity, 35

**M**

- Mammalian target of rapamycin, in neuroblastoma, 305
- MDM2 and ODC1 as *MYCN* targets, in neuroblastoma, 307–308
- Medical education, faculty development and educational scholarship in, 138–140
  - issues within, 134–144
- Menarche, premature, 251–252
- Meningitis, bacterial, cochlear implants and, 285
  - caused by human *Parechoviruses*, 71–72
- Meningococcal vaccines, 51–53
- Mental health disorders, psychotropic medication to treat, overdependence on, 154
- Metabolic syndrome, antipsychotics and, 171
- Millennium Development Goal #4, reduction of child mortality as goal of, 13, 14
- Mortality, child, reduction of, as Millennium Development Goal #4, 13, 14

**N**

- Necrotizing enterocolitis, human *Parechoviruses* in, 74
- Nelson, Waldo E., MD (1898–1997), as editor of *Journal of Pediatrics*, 4
  - awards given to, 8–9
  - “birds, for the” and, 7–8
  - giant in pediatrics, **1–10**
  - influence on/of family, 2
  - Nelson Textbook of Pediatrics* and, 1–2
  - personality of, 3–4
  - positive influence of, 3
  - professional career of, 5–7
  - story of life of, 4–5
- Neuroblastoma, **297–311**
  - classification and staging of, 299–301
  - clinical presentation of, 298–299
  - current research milestones and novel therapies in, 305–309
  - diagnosis of, 303
  - epidemiology of, 297–298
  - genomics of, 302–303
  - treatment of, 303–305
- Noonan syndrome, recombinant human growth hormone therapy in, 219
- Nutritional interventions, for prevention of atopic disease, 27–29
- Nutritional recommendations, for pediatric patient, update on, **27–39**

**P**

- Pancreatitis, recombinant human growth hormone therapy and, 229
- Parechoviruses*, human, **65–85**
  - acute flaccid paralysis caused by, 72–73
    - cell culture and, 79–80
    - central nervous system infections caused by, 70–73
    - clinical syndromes caused by, 70
    - encephalitis caused by, 73
    - epidemiology of, 68–70
    - gastrointestinal disease caused by, 75–76
    - genome, organization of, 66
    - historical background of, 65–66
    - in hemorrhage-hepatitis syndrome, 74
    - in necrotizing enterocolitis, 74
    - meningitis caused by, 71–72
    - neonatal disease caused by, 73–74
    - nucleic acid amplification for detection of, 78–79
    - prevention and control of, 81
    - respiratory disease caused by, 76–77

- Parechoviruses (*continued*)
- reverse transcription-polymerase chain reaction for detection of, 78–79
  - serology in, 80
  - sudden infant death and, 77
  - syndromes associated with, 77–78
  - testing for, specimen selection for, 80
  - undifferentiated febrile illness caused by, 73–74
  - virology of, 66–68
- Patient safety, medical education and, 123–127
- Pediatric education, and pediatric initiatives to improve education, 140–143
- collaboration in, 143–144
  - now and in future, 145
  - past decade in, 123–151
  - societal factors with implications for, 123–134
- Pediatric vaccines, 55–56
- Physicians, need for more, recognition of, medical education and, 131–133
- Poliomyelitis, cases in endemic countries, 57
- Prader-Willi syndrome, mortality in, recombinant human growth hormone therapy and, 222–223
- short stature in, 215
- Prebiotics, 36–37
- Precocious puberty. *See* *Puberty, precocious.*
- Primary Health Care (1978), 12
- Probiotics, 36–37
- Prolactin levels, antipsychotics and, 170–171
- Psychopharmacology, pediatric, 158–173
- controversies surrounding, 153–179
- Puberty, abnormal, in girls, age at, 246
- development of, variations of, 248–256
  - normal, review of, 243–244
  - precocious, central, 252–255
    - diagnosis in boys, 252
    - diagnosis in girls, 252
    - treatment of, benefit of, 252–254
    - methods of, 254–255
  - definition of, 244–246
  - environmental exposure to sex steroids and, 256
  - gonadotropin-independent, in
    - boys, 255–256
    - in girls, 255
  - in boys, 246–247
  - update on, 243–258
- Pubic hair, early, hormonal testing in, 249
- Pyloric stenosis, infantile hypertrophic, 195–206
- environmental factors in, 202–203
  - epidemiology of, 199–201
  - evaluation in, 196–197
  - genetics of, 201–202
  - pathogenesis of, 195–196
  - treatment/management of, 197–199
- Pyloromyotomy, in infantile hypertrophic pyloric stenosis, 197–198
- 
- Q**
- Quality improvement movement, medical education and, 127–128
- 
- R**
- Renal insufficiency, chronic, before transplantation, recombinant human growth hormone therapy and, 212–214
- Respiratory disease, caused by human *Parechoviruses*, 77
- Retinoic acid, in neuroblastoma, 305
- Reverse transcription-polymerase chain reaction, for detection of human *Parechoviruses*, 78–79
- Ricketts, vitamin D intake and, 33
- Rotavirus vaccines, 55–56
- Rufinamide, 268
- 
- S**
- School-based health centers, as model for provision of adolescent primary care, 113–121
- case study of, 113–114
  - collaboration in, 116–117
  - financing of, 117
  - history of, 114–115
  - impact of, 117–118
  - in Denver, case study of, 118–120
  - models of care by, 115
  - quality initiatives of, 117
  - services offered at, 115–116
- Scoliosis, recombinant human growth hormone therapy and, 228–229
- Seizures, causes of, 263, 264
- classification of, 260
- Selective serotonin reuptake inhibitors, 158–164
- adverse effects of, 161–162
  - dosage of, 162
  - fetal exposure to, 163
  - in autism, 163–164
  - monitoring children on, 161

serotonin syndrome and, 162  
“SSRI addiction” and, 162  
suicidal ideation and, 159–160

Serial transverse enteroplasty, in pediatric intestinal failure, 191

Serotonin syndrome, selective serotonin reuptake inhibitors and, 162

Short bowel syndrome, 181

Short stature, idiopathic, recombinant human growth hormone therapy in, 216–218

Short stature homeobox deficiency, recombinant human growth hormone therapy in, 218–219

Small for gestational age, recombinant human growth hormone therapy in, 215–216

Spasms, infantile, 269–270

Status epilepticus, treatment of, 271–272

Stimulants/stimulant alternatives, 164–168  
effects on growth, 164  
for preschoolers, 166–167  
monitoring use of, 167  
substance abuse potential of, 166  
sudden cardiac death and, 165–166  
tics caused by, 164–165

Sudden infant death, human *Parvovirus* and, 77

---

**T**

---

Technology, advances in, medical education and, 128–131

Tetanus, diphtheria, and acellular pertussis containing vaccine (Tdap), 50–51

Thelarche, premature, 250–251

Treatment models, empirically driven, 155–158

Tropomyosin kinases, in neuroblastoma, 306

Turner syndrome, mortality in, 223  
short stature in, 214–215

---

**V**

---

Vaccine(s), childhood combination, on horizon, 56–57  
influenza. See *Influenza vaccines*.  
international news on, 57–58  
meningococcal, 51–53  
pediatric, 55–56  
rotavirus, 55–56  
used in special circumstances, changes in recommendations for, 57

Vagus nerve stimulator, in epilepsy management, 273

Vigabatrin, 269–270

Vitamin D intake, for infants, 33–35